Literature DB >> 1833075

Pristane-induced arthritis in mice. III. Lymphocyte phenotypic and functional abnormalities precede the development of pristane-induced arthritis.

P H Wooley1, J D Whalen.   

Abstract

Pristane injection caused mediastinal lymphadenopathy in arthritis-susceptible DBA/1 mice, but not in arthritis-resistant DBA/2 mice. Early DBA/1 mediastinal lymph node changes were characterized by the accumulation of surface Ig+ cells and a CD8+ (Lyt 2) lymphocyte population, causing an inversion of the CD4/CD8 ratio. Depressed mitogen responses and the appearance of a nonspecific suppressor cell population were coincidental with the CD8+ cell accumulation. Prior to the development of overt clinical arthritis, an expansion of CD4+ (L3T4) lymphocytes displaced CD8+ as the predominant phenotype in mediastinal node. Mitogen responses were restored and suppressor cell activity was abrogated concomitant with the expansion of the CD4+ cell population.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833075     DOI: 10.1016/0008-8749(91)90150-a

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

Review 1.  Adjuvants and lymphoma risk as part of the ASIA spectrum.

Authors:  Dana Butnaru; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Alterations of lymphocyte populations in lymph nodes but not in spleen during the latency period of adjuvant arthritis.

Authors:  M Rodríguez-Palmero; C Pelegrí; M J Ferri; M Castell; A Franch; C Castellote
Journal:  Inflammation       Date:  1999-04       Impact factor: 4.092

Review 3.  Role of animal models in the study of drug-induced hypersensitivity reactions.

Authors:  Jack Uetrecht
Journal:  AAPS J       Date:  2006-01-13       Impact factor: 4.009

4.  Staphylococcal enterotoxin B increases the severity of type II collagen induced arthritis in mice.

Authors:  P H Wooley; B Cingel
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

5.  Effect of Mycoplasma arthritidis superantigen on enzymatically induced arthritis in mice.

Authors:  H Sustackova; C A Chambers; N Hozumi; R A Kandel; P A Quinn; T F Cruz
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

6.  Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the at-risk phase of autoantibody positive rheumatoid arthritis.

Authors:  Tamara H Ramwadhdoebe; Janine Hähnlein; Karen I Maijer; Leonard J van Boven; Danielle M Gerlag; Paul P Tak; Lisa G M van Baarsen
Journal:  Eur J Immunol       Date:  2016-10-12       Impact factor: 5.532

7.  Molecular Characterization of Human Lymph Node Stromal Cells During the Earliest Phases of Rheumatoid Arthritis.

Authors:  Emmanuel Karouzakis; Janine Hähnlein; Cristoforo Grasso; Johanna F Semmelink; Paul P Tak; Danielle M Gerlag; Steffen Gay; Caroline Ospelt; Lisa G M van Baarsen
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

8.  The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis.

Authors:  L G M van Baarsen; M J H de Hair; T H Ramwadhdoebe; I J A J Zijlstra; M Maas; D M Gerlag; P P Tak
Journal:  Ann Rheum Dis       Date:  2013-05-09       Impact factor: 19.103

Review 9.  Gene expression analysis in RA: towards personalized medicine.

Authors:  A N Burska; K Roget; M Blits; L Soto Gomez; F van de Loo; L D Hazelwood; C L Verweij; A Rowe; G N Goulielmos; L G M van Baarsen; F Ponchel
Journal:  Pharmacogenomics J       Date:  2014-03-04       Impact factor: 3.550

10.  Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis.

Authors:  Janine S Hähnlein; Reza Nadafi; Tineke de Jong; Tamara H Ramwadhdoebe; Johanna F Semmelink; Karen I Maijer; IJsbrand A Zijlstra; Mario Maas; Danielle M Gerlag; Teunis B H Geijtenbeek; Paul P Tak; Reina E Mebius; Lisa G M van Baarsen
Journal:  Arthritis Res Ther       Date:  2018-02-26       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.